MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.radonc.2025.111258

Медицинская библиотека · Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2025

Bridging radiotherapy for chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma: Systematic review and meta-analysis.

Lam Eric Ka-Ming, Luk Mai Yee, Yuen Kwok Keung, Cheung Ben Man-Fei

СтатьяМетаанализСистематический обзорПеревод пока не подготовлен

Аннотация

BACKGROUND AND PURPOSE: Bridging therapy is often needed for relapsed/refractory non-Hodgkin lymphoma (NHL) receiving chimeric antigen receptor T cells (CART) therapy. Bridging radiotherapy (BRT) is often adopted, but its benefit is uncertain. Here, we performed a systematic review and meta-analysis to study the adoption of BRT in CART therapy.

MATERIALS AND

METHODS

PubMed, MEDLINE and EMBASE were searched until 13 April 2025 for adult NHL studies adopting BRT before CART therapy. Primary endpoints were 1-year overall survival (OS) and progression-free survival (PFS); secondary endpoints were objective response rate (ORR), in-field failure and grade ≥ 3 cytokine-release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). Random-effects model was used for pooled estimates. Meta-regression was done to explore clinical covariates.

RESULTS

Fifteen studies including 636 patients were reviewed. Pooled 1-year OS was 67 % and 1-year PFS was 52 %. Pooled ORR was 79 % with complete response rate of 57 %. Pooled in-field failure was 11 %. Pooled Grade ≥ 3 CRS was 5 % while Grade ≥ 3 ICANS was 6 %. Bulky, extra-nodal or advanced-stage disease were associated with worse 1-year OS but not with 1-year PFS nor CART toxicity. Comprehensive BRT covering all lesions was associated with improved 1-year PFS and RT doses > 30  Gy EQD2 was associated with 1-year PFS.

CONCLUSION

BRT leads favourable survival outcome and durable local control while maintaining low rate of severe CRS/ICANS. Comprehensive, adequately dosed irradiation may optimise tumour-burden reduction and improve 1-year PFS. Further prospective studies are warranted to refine RT dose, field coverage and patient selection.

Для цитирования: Lam Eric Ka-Ming, Luk Mai Yee, Yuen Kwok Keung, Cheung Ben Man-Fei. Bridging radiotherapy for chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma: Systematic review and meta-analysis.. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2025. DOI: 10.1016/j.radonc.2025.111258.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.